Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naïve nAMD associated with type 1 CNV....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2021-03, Vol.11 (1), p.6759-6759, Article 6759
Hauptverfasser: Matsumoto, Hidetaka, Hoshino, Junki, Mukai, Ryo, Nakamura, Kosuke, Akiyama, Hideo
Format: Artikel
Sprache:eng
Schlagworte:
692/308
692/308/409
Acuity
Age
Angiography
Eye
Humanities and Social Sciences
Inflammation
Lesions
Macular degeneration
Monoclonal antibodies
multidisciplinary
Science
Science (multidisciplinary)
Steroid hormones
Steroids
Vascular diseases
Vascularization
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naïve nAMD associated with type 1 CNV. Three monthly injections of brolucizumab were completed in 36 eyes (85.7%). In those cases, best-corrected visual acuity (BCVA) was 0.24 ± 0.27 at baseline and improved significantly to 0.12 ± 0.23 after 3 months ( P  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-86014-7